These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31262769)

  • 1.
    Asempa TE; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem/Cilastatin/Relebactam Alone and in Combination against
    Chen IH; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33139283
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
    J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Kurihara D; Matsumoto S; Kishi N; Ishii Y; Mori M
    Microbiol Spectr; 2022 Apr; 10(2):e0223521. PubMed ID: 35416695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
    Young K; Painter RE; Raghoobar SL; Hairston NN; Racine F; Wisniewski D; Balibar CJ; Villafania A; Zhang R; Sahm DF; Blizzard T; Murgolo N; Hammond ML; Motyl MR
    BMC Microbiol; 2019 Jul; 19(1):150. PubMed ID: 31272373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):212-215. PubMed ID: 31174995
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
    Fraile-Ribot PA; Zamorano L; Orellana R; Del Barrio-Tofiño E; Sánchez-Diener I; Cortes-Lara S; López-Causapé C; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model.
    Reyes S; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2020 Aug; 75(8):2197-2205. PubMed ID: 32386408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Gueny ME; Sahm DF
    J Antimicrob Chemother; 2019 Aug; 74(8):2284-2288. PubMed ID: 31086960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an
    Rico Caballero V; Almarzoky Abuhussain S; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
    Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Mikhail S; Singh NB; Kebriaei R; Rice SA; Stamper KC; Castanheira M; Rybak MJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
    Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
    Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019.
    Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Golden A; Lagace-Wiens P; Zhanel GG;
    Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115418. PubMed ID: 34102373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Porins and bla
    Balabanian G; Rose M; Manning N; Landman D; Quale J
    Microb Drug Resist; 2018 Sep; 24(7):877-881. PubMed ID: 29782237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Lob SH; Hackel MA; Kazmierczak KM; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.
    Karlowsky JA; Lob SH; Kazmierczak KM; Hawser SP; Magnet S; Young K; Motyl MR; Sahm DF
    J Antimicrob Chemother; 2018 Jul; 73(7):1872-1879. PubMed ID: 29659861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.